Menu Breaking news sponsored byWith a $96.0 billion market value, Gilead Sciences Inc (NASDAQ:GILD) ranks in the top 10% of its industry group, Biotechnology, and in the top decile of sector group, Health Care, in market value. From the vantage point of investment attractiveness, The current Portfolio Grader ranking for GILD puts it 222 among the 349 companies in this industry group, giving it a lower than average position; in the third quartile of the sector with a ranking of 524 among the 785 companies in the sector, and number 3,340 in the nearly 5,000 company Portfolio Grader universe.GILD has a current recommendation of Sell using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.Currently, Portfolio Grader ranks the Health Care sector number 10 among the 12 sectors in its universe putting it in the bottom quartile of all the GICS sectors. The Biotechnology industry group is ranked 50 among the 69 industry groups within the GICS sectors, placing it below-average in terms of the Navellier scoring system.GILD scores are below-average in 3 of the 8 fundamental metrics used by Portfolio Grader in the ranking of company stocks.The company's operational scores are a source of great concern with a ranking for sales growth, operating margin and earnings growth that are considerably below average.  Scores for visibility of earnings are superior with a ranking for earnings revisions, earnings surprises and earnings momentum that are discernibly better than average. GILD's grades for cash flow and return on equity are better than its industry group average.  Gilead Sciences' fundamental scores give GILD a place in the top quartile of the industry group. Quantitatively, Portfolio Grader uses the Navellier Proprietary Quantitative Score to measure GILD's shares from the aspect of risk/reward. This unique scoring methodology assesses the relative value of GILD's shares based on the current price of the shares relative to its peers, the market and risk associated with its industry and sector groups. Considering this risk/reward calculation, the company currently scores below-average in its industry group compared to its peers.Louis Navellier's proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results, with A being 'strong buy' and F being 'strong sell'.  Explore the tool here.Commentary provided by UpTick Data Technologies.Article printed from InvestorPlace Media, https://investorplace.com/2017/11/rating-on-gilead-sciences-gild-stock-drops-to-sell/.©2017 InvestorPlace Media, LLC

								About Us							
							  ·  													
								Press Center							
							  ·  													
								Resources							
							  ·  													
								Advisory Services							
							  ·  													
								Free Newsletters							
							  ·  													
								Free Reports							
							  ·  													
								Contact Us							
							  ·  													
								Advertise With Us							
							  ·  													
								Employment							
							  ·  													
								Privacy							
							  ·  													
								Terms and Conditions							
							  ·  													
								Disclosures and Disclaimers							
							  ·  													
								Media Sites							


								RSS							
							  ·  													
								Sitemap							

More On InvestorPlace:
Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.Copyright © 2017 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.